Vibalogics is creating a 110,000-sf facility for the production of oncolytic viruses, viral vector vaccines, and viral vector gene therapy products in Boxborough, Mass. Supporting late-phase clinical and commercial manufacturing operations, the highly flexible structure will include 2,000-liter bioreactors, multiple cGMP production suites, offices, warehouse space, and labs for research, development, and quality control. The $150 million project involves the renovation of an existing R&D building previously occupied by Cisco Systems. DPS Group is providing design, engineering, and construction management services for the facility, which will meet the Centers for Disease Control and Prevention's guidelines for Biosafety Level 2 Large Scale (BSL-2LS). The project incorporates the use of traditional construction methods in combination with Germfree's turnkey modular cleanrooms. Completion is expected in mid-2021.
Vibalogics, a global contract development and manufacturing organization, is partnering with Janssen Pharmaceuticals to produce its investigational COVID-19 vaccine candidate.